Text Size
50 studies found for:    "NJMS" OR "New Jersey Medical School" | Open Studies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children
Condition: Congenital Nasolacrimal Duct Obstruction
Interventions: Drug: Besifloxacin;   Drug: polymyxin b/trimethoprim - ophthalmic
2 Unknown † Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Conditions: Heart Failure, Congestive;   Dyspnea;   Pulmonary Edema
Intervention: Drug: Nesiritide
3 Recruiting Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Condition: Influenza, Human
Interventions: Drug: Oseltamivir;   Drug: Oseltamivir Placebo
4 Recruiting TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
Condition: Pulmonary Tuberculosis
Interventions: Drug: rifampin;   Drug: rifapentine
5 Recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
6 Recruiting Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir;   Drug: Oseltamivir
7 Recruiting Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
8 Recruiting Pilon Fracture Reduction and Functional Outcome
Condition: Pilon Fracture of Tibia
Intervention:
9 Recruiting Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
10 Recruiting Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Drug: tirapazamine
11 Available An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
Condition: HIV Infection
Intervention: Drug: Efavirenz
12 Recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
13 Recruiting Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Neurofibrosarcoma;   Chondrosarcoma;   Endometrial Stromal Sarcoma;   Mast Cell Sarcoma;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Ovarian Carcinosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib;   Other: laboratory biomarker analysis
14 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Transitional Cell Carcinoma of the Bladder;   Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
15 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
16 Recruiting Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Drug: lenalidomide
17 Recruiting Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: FOLFOX regimen;   Drug: selumetinib
18 Recruiting Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage IB Cervical Cancer;   Stage II Endometrial Carcinoma;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage IVA Cervical Cancer
Interventions: Drug: ferumoxtran-10;   Procedure: diagnostic lymphadenectomy;   Procedure: axillary lymph node biopsy;   Procedure: 3-Tesla magnetic resonance imaging;   Procedure: positron emission tomography/computed tomography;   Radiation: fludeoxyglucose F 18
19 Recruiting Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
20 Recruiting Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance;   Atypical Endometrial Hyperplasia;   Atypical Glandular Cell of Undetermined Significance;   Cervical Cancer;   Cervical Intraepithelial Neoplasia Grade 2;   Cervical Intraepithelial Neoplasia Grade 3;   Human Papilloma Virus Infection
Intervention: Other: laboratory biomarker analysis
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years